VYNE Therapeutics Shares Surge Following Merger Announcement

VYNE Therapeutics shares are trading higher after the company announced a merger agreement with Yarrow Bioscience, backed by a $200 million financing commitment and plans to advance a promising autoimmune thyroid disease treatment.